BioXcel Therapeutics (BTAI) Misses Q3 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
BioXcel Therapeutics (BTAI) Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
November 11, 2020 7:07 AM ESTBioXcel Therapeutics, Inc. (BTI or the Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that it has completed its pre-NDA meeting with the FDA for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders. BXCL501, which received Fast Track designation from the FDA, is the Companys novel, proprietary, orally dissolving, sublingual thin film formulation of dexmedetomidine (Dex). The purpose of the meeting was to discuss the FDAs expectations regarding the content and formatting of the NDA submission... More
